SIX1 and hepatocellular carcinoma: Our data provided the first evidence that miR‐204‐5p regulated HCC proliferation through the miR‐204‐5p/SIX1 pathway, suggesting that miR‐204‐5p and SIX1 could be potential therapeutic targets for HCC treatment.